Get the Stockscreener App
0.092
7.07%
-0.007
After Hours:
.09
-0.002
-2.17%
Eyenovia Inc stock is traded at $0.092, with a volume of 14.47M.
It is down -7.07% in the last 24 hours and down -81.93% over the past month.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
See More
Previous Close:
$0.099
Open:
$0.0988
24h Volume:
14.47M
Relative Volume:
3.06
Market Cap:
$8.78M
Revenue:
-
Net Income/Loss:
$-37.28M
P/E Ratio:
-0.1333
EPS:
-0.69
Net Cash Flow:
$-32.24M
1W Performance:
+3.49%
1M Performance:
-81.93%
6M Performance:
-88.61%
1Y Performance:
-93.57%
1-Day Range:
$0.0902
$0.0988
1-Week Range:
$0.085
$0.1148
52-Week Range:
$0.079
$2.57
Eyenovia Inc Stock (EYEN) Company Profile
Name
Eyenovia Inc
Sector
Industry
Phone
813-766-9539
Address
295 MADISON AVENUE,, NEW YORK, NY
Compare EYEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYEN
Eyenovia Inc
|
0.092 | 8.78M | 0 | -37.28M | -32.24M | -0.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.73 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.34 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
617.49 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.01 | 32.63B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.20 | 28.10B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-01-21 | Initiated | Northland Capital | Outperform |
| Feb-03-20 | Downgrade | Oppenheimer | Outperform → Perform |
Eyenovia Inc Stock (EYEN) Latest News
Eyenovia’s Direct Offering to Support Strategic Initiatives - TipRanks
SEC Form 424B5 filed by Eyenovia Inc. - Quantisnow
Eyenovia secures $1.3 million in direct offering By Investing.com - Investing.com South Africa
Eyenovia defers loan payments, issues equity to lenders - Investing.com
Eyenovia defers loan payments, issues equity to lenders By Investing.com - Investing.com Canada
Eyenovia Slumps On Pricing Of Registered Direct Offering - Nasdaq
Eyenovia Restructures Finances and Leadership Team - TipRanks
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering - The Manila Times
Eyenovia secures $1.3 million in direct offering - Investing.com
Eyenovia Raises $1.3M in Direct Offering at $0.1076 Per Share with Warrants | EYEN Stock News - StockTitan
Eyenovia taking additional actions to reduce personnel-related costs by over 70% - Yahoo Finance
Eyenovia secures debt payment deferral from Avenue Capital By Investing.com - Investing.com Nigeria
Eyenovia Continues to Evaluate Broad Range of Strategic Alternatives to Maximize Stakeholder Value - Marketscreener.com
Eyenovia secures debt payment deferral from Avenue Capital - Investing.com
Eyenovia Provides Update on Restructuring Efforts - The Manila Times
Eyenovia Provides Update on Restructuring Efforts - GlobeNewswire Inc.
Eyenovia reports low cash reserves; in talks for debt restructuring By Investing.com - Investing.com South Africa
Eyenovia reports low cash reserves; in talks for debt restructuring - Investing.com
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study - MSN
Eyenovia downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
William Blair Reaffirms “Market Perform” Rating for Eyenovia (NASDAQ:EYEN) - Defense World
Eyenovia (NASDAQ:EYEN) Earns Hold Rating from Brookline Capital Management - Defense World
Eyenovia stock plummets following Phase III myopia trial failure - Clinical Trials Arena
Black Friday for Eyenovia as shares fall 70% - The Pharma Letter
Eyenovia stock downgraded to Neutral, price target set on challenges By Investing.com - Investing.com UK
Eyenovia halts myopia study after missing primary endpoint - Investing.com India
Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study - Marketscreener.com
Eyenovia to Cut 50% of Workforce After Phase 3 Study Disappoints - MarketWatch
Eyenovia to end eye drug study, cut 50% of its workforce - Reuters
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline - AOL
Eyenovia Shares Plumb New Depths After Study Failure - MarketWatch
Eyenovia Shares Plummet 70% After It Drops Lead Program - BioSpace
Eyenovia plunges as late-stage trial for myopia treatment fails - MSN
Eyenovia stock plunges after trial setback (EYEN:NASDAQ) - Seeking Alpha
Eyenovia discontinues late-stage eye drug study, shares fall - XM
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Eyenovia Inc - GuruFocus.com
Eyenovia Mulls Options After Phase 3 Study Failure - MarketWatch
Eyenovia Provides Update on Phase 3 CHAPERONE Study - The Manila Times
Eyenovia Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Eyenovia's Phase 3 Myopia Drug Trial Fails Primary Endpoint, Company Weighs Options | EYEN Stock News - StockTitan
Eyenovia, Inc. (NASDAQ:EYEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Eyenovia Inc Stock (EYEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eyenovia Inc Stock (EYEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rowe Michael M | Chief Executive Officer |
Aug 26 '24 |
Buy |
0.57 |
50,000 |
28,500 |
82,927 |
| Grant Stuart M. | 10% Owner |
Jul 02 '24 |
Buy |
0.66 |
1,515,151 |
1,000,000 |
10,914,153 |
| Grant Stuart M. | 10% Owner |
Mar 28 '24 |
Buy |
0.98 |
100,000 |
98,000 |
5,430,715 |
| Grant Stuart M. | 10% Owner |
Mar 19 '24 |
Buy |
1.23 |
50,000 |
61,500 |
5,330,715 |
| Grant Stuart M. | 10% Owner |
Mar 08 '24 |
Buy |
1.58 |
10,717 |
16,911 |
5,280,715 |
| Rowe Michael M | Chief Executive Officer |
Dec 04 '23 |
Buy |
1.36 |
4,890 |
6,650 |
32,927 |
1.58%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):